E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
E.1.1.1 | Medical condition in easily understood language |
Melanoma is a type of cancer that develops from the pigment-containing cells known as melanocytes |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cancer [C04] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10053571 |
E.1.2 | Term | Melanoma |
E.1.2 | System Organ Class | 100000004864 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To estimate the frequency of the v-raf murine sarcoma viral oncogene homolog B1 (BRAF) V600 mutation in a new mutation analysis triggered by a mutant plasma cell-free DNA (cfDNA) test result, for patients with BRAF wild-type status based on a prior test result on tissue |
|
E.2.2 | Secondary objectives of the trial |
To investigate the clinical outcome of all patients, as well as broken down for patients for whom treatment is based on the mutation identified by the prior test result on tissue, and patients for whom treatment is based upon the mutation identified on the new tissue analysis, triggered by the mutant plasma cfDNA test result
To investigate the correlation of the initial concentration of the BRAF V600 mutation on cfDNA in plasma with progression-free survival time and duration of response, for all treated patients
To estimate the sensitivity and specificity, and the positive and negative predictive value of the results of plasma testing with respect to the prior test result on tissues
To characterize the toxicity profile in patients receiving vemurafenib plus cobimetinib |
|
E.2.3 | Trial contains a sub-study | Yes |
E.2.3.1 | Full title, date and version of each sub-study and their related objectives |
Presence and concentration of the BRAF V600 mutation and the NRAS mutation measured on plasma cfDNA will be recorded during treatment with vemurafenib and cobimetinib.
(Please refer to the protocol) |
|
E.3 | Principal inclusion criteria |
General inclusion criteria:
- Male or female patient aged >= 18 years
- Eastern Coorperative Oncology Group (ECOG) Performance Status of 0-
2
- Adequate hematologic and end organ function (renal and liver)
- Negative serum pregnancy test prior to commencement of dosing in
women of childbearing potential
- Absence of any psychological, familial, sociological, or geographical
condition that potentially hampers compliance with the study protocol
and treatment regimen and follow-up after treatment discontinuation
schedule; those conditions should be discussed with the patient before
trial entry
- Female patients of childbearing potential and male patients with
partners of childbearing potential must agree to always use 2 effective
forms of contraception during the course of this study and for at least 6
months after completion of study therapy
a. Females of childbearing potential are defined as sexually mature
women without prior oophorectomy or hysterectomy who have had
menses within the last 12 months.
b. Females are not considered to be of childbearing potential if
amenorrheic for > 12 months but < 2 years and follicle-stimulating
hormone (FSH) level > 40 IU/L.
c. Effective forms of contraception include surgical sterilization, a
reliable barrier, method with spermicide, birth control pills, or
contraceptive hormone implants. Please note that potential interactions
between vemurafenib and hormonal contraceptives may decrease the
effectiveness of hormonal contraceptives.
d. d. Male patients who are surgically sterilized are required to use
barrier methods of contraception
Disease-specific Inclusion Criteria:
- Patients with histologically confirmed cutaneous melanoma, either
unresectable Stage IIIc or Stage IV metastatic melanoma, as defined by
AJCC 7th edition
- Documentation of BRAF V600 mutation-positive status in melanoma
tumor tissue using a validated tissue test
- Patients with measurable or non-measurable disease (Response
Evaluation Criteria in Solid Tumors version 1.1) |
|
E.4 | Principal exclusion criteria |
Cancer-Related Exclusion Criteria:
1. History of prior RAF or mitogen-activated protein kinase (MEK)
pathway inhibitor treatment
2.
a.Palliative radiotherapy within 14 days prior to the first dose of study
treatment
b. Use of prior chemotherapy or immunotherapy (incl. treatment with an
anti-PD1, or anti-PDL1 or anti-CTLA-4 monoclonal antibody) within 4
weeks before first study drug administration
Exclusion Criteria Based on Organ Function:
- Ocular: Evidence of retinal pathology on ophthalmologic examination
that is considered a risk factor for neurosensory retinal detachment/
central serous chorioretinopathy, retinal vein occlusion, or neovascular
macular degeneration
- Patients will be excluded if they have one of the following conditions:
a) Uncontrolled glaucoma with intra-ocular pressures >= 21 mmHg b)
Uncontrolled hypercholesterolemia >= Grade 2 c) Hypertriglyceridemia
>= Grade 2 d) Hyperglycemia >= Grade 2
- Cardiac: History of clinically significant cardiac dysfunction
General exclusion criteria:
- Current severe, uncontrolled systemic disease
- Major surgery or traumatic injury within 14 days prior to first dose of
study treatment
- History of malabsorption or other condition that would interfere with
absorption of study drugs
- the following foods/supplements are prohibited at least 7 days prior
to initiation of and during study treatment:
a) St. John's wort or hyperforin (potent CYP3A4 enzyme inducer)
b) Grapefruit juice (potent cytochrome P450 CYP3A4 enzyme inhibitor) |
|
E.5 End points |
E.5.1 | Primary end point(s) |
1. BRAF V600 mutation status determined on plasma cfDNA at onset of the study
2. BRAF V600 mutation status determined on tissue
3. Occurrence of the BRAF V600 mutation on the new mutation analysis for patients with a BRAF wild-type based on a prior tissue test result and a mutation determined on plasma cfDNA |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Pre-screening period (Day -56 to Day -1) |
|
E.5.2 | Secondary end point(s) |
1. Objective response rate
2. Progression-free survival
3. Duration of response
4. Overall survival
5. Incidence, nature and severity of adverse events, serious adverse events, and adverse events of special interest, graded according to National Cancer Institute Common Toxicity Criteria for Adverse Events v 4.03
6. Changes in vital signs, electrocardiograms and clinical lab results during the course of the study |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | Yes |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | Yes |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 1 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 3 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 14 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
The study will end when all patients enrolled have been followed for 4 weeks after study treatment discontinuation, death by any cause, withdrawal of consent, or lost to follow-up; 18 months after enrollment of last patient in the study; or the Sponsor decides to end the trial, whichever occurs first. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 11 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 2 |
E.8.9.2 | In all countries concerned by the trial months | 11 |